MedPath

Axumin

These highlights do not include all the information needed to use AXUMIN safely and effectively. See full prescribing information for AXUMIN. AXUMIN (fluciclovine F 18) injection, for intravenous use Initial U.S. Approval: 2016

Approved
Approval ID

389a502e-a7d5-43dd-b6bf-f022ff23f3b9

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 8, 2023

Manufacturers
FDA

Blue Earth Diagnostics

DUNS: 219742530

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Fluciclovine F-18

PRODUCT DETAILS

NDC Product Code69932-001
Application NumberNDA208054
Marketing CategoryC73594
Route of AdministrationINTRAVENOUS
Effective DateDecember 8, 2023
Generic NameFluciclovine F-18

INGREDIENTS (5)

SODIUM CITRATE, UNSPECIFIED FORMInactive
Code: 1Q73Q2JULR
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
FLUCICLOVINE F-18Active
Quantity: 221 mCi in 1 mL
Code: 38R1Q0L1ZE
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Axumin - FDA Drug Approval Details